Thijs van Haaps/LinkedIn
Oct 29, 2025, 07:38
Thijs van Haaps and Team Show That Andexanet Alfa May Go Beyond Apixaban and Rivaroxaban
RPTH Journal shared a post on LinkedIn:
“New in RPTH!
Thijs van Haaps and team show that Andexanet alfa may go beyond apixaban and rivaroxaban—showing reversal potential for enoxaparin. In both healthy volunteers and bleeding patients, anti-Xa activity fell rapidly and 88% achieved good hemostasis.”
Title: Andexanet Alfa for the Reversal of the Low-Molecular-Weight Heparin Enoxaparin
Authors: Thijs F. van Haaps, Alexander P. Benz, Lizhen Xu, Saskia Middeldorp, John W. Eikelboom, Truman J. Milling, Jr., Mark Crowther, Lisa Holer, Stephan Nolan, Per Ladenvall, Genmin Lu, Michiel Coppens
Read more here.
Stay updated with Hemostasis Today.
-
Feb 2, 2026, 07:12The 2026 Application Cycle for ASH’s International Outreach Initiative is Now Open – ASH
-
Feb 1, 2026, 13:32Shiny K. Kajal: A Series On Reaching the Diagnosis of Immune Thrombocytopenia
-
Feb 1, 2026, 13:26Mary Cushman: Association of Atrial Fibrillation with Risk of Incident Cognitive Impairment
-
Feb 1, 2026, 13:23Abdulrahman Katib: Extended Low-Dose DOAC May Reduce VTE Recurrence
-
Feb 1, 2026, 13:22Jeff June: The Stroke That Wasn’t New – Why ‘Cryptogenic’ Often Means Undetected
-
Feb 1, 2026, 13:11Panagiotis Doukas: Plasma Desmosine as a Biomarker of Increased Proteolytic Activity in the Aortic Wall
-
Feb 1, 2026, 12:54Pierpaolo Di Micco: Starting a New Era for Anticoagulant Treatments
-
Feb 1, 2026, 12:16Erwin Loh: Immunotherapy Reduces Plaque in Arteries of Mice
-
Feb 1, 2026, 12:06Ney Carter Borges: The Central Role of Endothelial Dysfunction in Cardiovascular Disease Progression